Introduction
Thiazide diuretics have been used for the treatment of hypertension for over 30 years and are considered to be a first-line therapy (1, 2) . Common indications for thiazide diuretics include elderly patients with isolated systolic hypertension or congestive heart failure, and randomized controlled trials have shown that thiazide treatment, often in combination with β-blockers, is effective in reducing morbidity and mortality (3) (4) (5) . Recently, an antihypertensive regimen based on indapamide has been shown to be effective in the secondary doses of thiazide diuretics might increase the risk of sudden death. In fact, the risk of cardiac arrest among patients receiving thiazide diuretics was 3-fold higher (10) , and cardiovascular mortality was 3.8-fold higher in diabetics receiving diuretics (11) . This may be attributable to the adverse metabolic effects of thiazides, such as hypokalemia, glucose intolerance, changes in serum cholesterol and triglyceride levels and/or hyperuricemia. Recent studies have demonstrated that the metabolic effects of thiazides are dose-dependent (12) . In addition, the National Interventional Cooperative Study in Elderly Hypertension (NICS-EH) reported that treatment with diuretics resulted in a higher incidence of adverse reactions than treatment with calcium channel blockers (13) .
Sodium intake in Japanese is still higher than that in Caucasians. In one survey in the Okinawa district, sodium intake has been reported to be 10.7 g/day for men and 10.3 g/day for women (14) . Diuretics might be very effective to lower blood pressure in hypertensives with a higher sodium intake. In the present study, we investigated the effects of the diuretic, indapamide, on blood pressure as well as on potassium, glucose, lipids and uric acid levels. We utilized a low dose of this drug, a 1 mg tablet, which is half of the usual recommended dose, in an attempt to achieve an adequate blood pressure effect without adverse changes in metabolic parameters. In addition, we administered the tablet every other day to reduce the dosage still further, since this tablet was hard to cut in half.
Methods

Subjects
Thirty patients with blood pressures greater than 140/90 mmHg (27 were under the medication, while 3 were untreated) were recruited from Saitama Medical School Hospital. Eight were males and 22 were females. The average age was 65.7 2.0 years, and the average duration of hypertension was 13.9 1.5 years. Fifteen patients had type 2 diabetes mellitus. Fourteen patients had hypercholesterolemia, 17 patients were obese (body mass index (BMI) >25 kg/m 2 ), 9 patients had a history of ischemic heart disease, 9 patients had non-symptomatic lacunar infarcts, and 5 patients had proteinuria. This study was approved by the clinical trial committee, Saitama Medical School, and informed consent was obtained from all subjects.
Study Design
Three patients received indapamide alone while others received indapamide in combination with other agents, which had been administered for more than the past 3 months: 5 patients received Ca-channel blockers (CCB), 7 patients received angiotensin converting enzyme inhibitors (ACEI), 5 patients received both CCB and ACEI, 6 patients received both CCB and β-blockers, and 4 patients received CCB, ACEI and α-blockers. Patients received 1 mg of indapamide every day for 3 months and then were switched to an everyother-day regimen for 3 months. The dosages of the concomitant antihypertensive medications were not altered. Blood pressure measurements were performed at baseline and after 3 months of each stable dose-regimen of indapamide. Measurements were performed in duplicate, 2 min apart in the sitting position after 10 min rest, using a sphygmomanometer. Blood pressures obtained on the two separate days at each period were averaged. Blood samples were obtained after overnight fasting, and serum levels of potassium, total cholesterol, triglycerides, high density lipoprotein (HDL)-cholesterol, creatinine and uric acid were determined with an automatic analyzer (7450, Hitachi, Tokyo, Japan). Glycosylated hemoglobin A1C (HbA1C) levels were measured by the HPLC method, and hematocrit was also determined. At the end of the study, 24-h ambulatory blood pressure monitoring (ABPM) was performed using ATM-2421 (A & D, Tokyo, Japan) in 11 patients every 30 min from 7:00 to 22:00 and every hour from 22:00 to 7:00 during the consecutive 48 h. This corresponded to one day in which the patient received indapamide and one day in which the patient did not receive indapamide. 24-h ABPM was randomized so that 5 patients started on the day with indapamide, whereas 6 patients started on the day without indapamide. The average day (7:00-22:00) and night (24:00-6:00) ABPM values were calculated separately for each day of the 2-day period.
Statistics
All data are expressed as the mean SEM. Statistical analyses were performed by paired or unpaired Student's t-test using StatView (Ver 5.0). Values of p<0.05 were considered to indicate statistical significance.
Results
Administration of 1 mg of indapamide resulted in a significant reduction in blood pressure (Table 1) , and the reduction was maintained after switching to an every-other-day regimen for 3 months. Blood pressure did not differ significantly between patients with diabetes mellitus and those without diabetes (Table 2) . Heart rate did not change with either regimen when compared to baseline. Changes in hematocrit, creatinine, uric acid, low density lipoprotein (LDL)-cholesterol, serum sodium, serum potassium, and HbA1C are summarized in Table 1 . Daily administration of 1 mg of indapamide resulted only in increased serum uric acid levels (5.6 0.3 to 6.1 0.3 mg/dl), with a subsequent normalization of uric acid levels when the patient was switched to an every-other-day regimen of indapamide (5.8 0.3 mg/dl). Neither regimen of indapamide resulted in changes in HbA1C levels. Metabolic parameters did not significantly differ between patients with and those without diabetes mellitus, as shown in Table 2 . These parameters were not different even in patients with diabetes, with the excep- 
Fig. 1. Time course of ambulatory blood pressure (ABP) over 24 h. No statistical difference was observed between ABP on the day when indapamide was administered and ABP on the day when indapamide was not given.
tion of a small but significant increase in uric acid when indapamide was administered every day ( Table 2 ). The time course of ABPM over 24 h is illustrated in Fig.  1 . No statistical difference in ABPM was observed between the day when indapamide was administered and the day when indapamide was not given. Average 24-h ABPM values are summarized in Table 3 . Although ABPM was slightly higher on the day that the patient did not receive indapamide, the difference was not statistically significant.
Discussion
The present study demonstrated that administration of a low dose of the diuretic, indapamide, resulted in a significant reduction in blood pressure that was nearly equal to those reported in the phase III clinical trial (15) , although in the present study the dose was not selected at random. Carlsen et al. demonstrated that decreasing doses of bendrofluazide resulted in reduced metabolic effects while still preserving the antihypertensive effects (12) . This is consistent with the present finding that the antihypertensive effect of indapamide was preserved when the regimen was switched to every-otherday administration. Further, the average ABPM measurements taken on the day that the patient received indapamide were not significantly different from those on the day in which the patient did not receive the drug. Although the plasma concentration of indapamide approaches zero on the day the patient does not receive the drug (indapamide halflife 7.5 or 18 h (16, 17) ), the antihypertensive effect is dependent on blood volume reduction secondary to natriuresis based on the lack of change in hematocrit between the periods when indapamide was administered every day or every other day.
A clear benefit of lower doses of the diuretic is the lack of effects on metabolic parameters. Daily administration of indapamide resulted only in a slight increase in serum uric acid levels, with no effect on serum potassium, LDL-cholesterol and HbA1C levels. Further, every-other-day administration of indapamide resulted in a normalization of the increased uric acid levels that were seen with daily administration. In randomized, placebo-controlled trials, low-dose diuretic therapy was associated with a 28% reduction in coronary heart disease when compared to high-dose diuretic therapy (5), possibly due to a reduced number of metabolic disturbances.
In the Puget Sound Group Health Cooperative case-control study (10) , moderate-or high-dose diuretic therapy (hydrochlorothiazide or chlorthalidone 50 or 100 mg daily) increased the odds ratio of cardiac arrest to 1.7 or 3.6, respectively. In addition, the risk of primary cardiac arrest among patients receiving combined thiazide and potassium-sparing diuretic therapy was reduced by 30% compared to patients treated with a thiazide alone. The Systolic Hypertension in the Elderly Program (SHEP) trial (3) used low doses of diuretics (12.5 to 25 mg of chlorthalidone) and demonstrated that total stroke, nonfatal myocardial infarction and coronary death, and major cardiovascular events were reduced by 27-36% when compared to the placebo group. However, even at low doses of diuretics, 7.2% of the diuretic-treated group had hypokalemia (<3.5 mEq/l) compared with 1% of the placebo group. After 1 year of treatment the risk of cardiovascular events, coronary events and stroke was 51-72% lower in those patients who had normal serum potassium levels compared to those who experienced hypokalemia (18) .
Thiazide is known to impair glucose tolerance and insulin resistance (7, 19) . In fact, thiazide administration with or without β-blockers or with amiloride increased the incidence of new-onset diabetes mellitus by 16-30% when compared to ACEI or CCB treatment (20, 21) . In the present study, there was no significant change in HbA1c with indapamide treatment.
One more point to be noted is that the every-other-day regimen of indapamide had a quality of life (QOL) advantage in addition to its efficacy in blood pressure lowering. Namely, if the patients forgot to take their medicine, they were able to take it on the next day and, as a result, there were no remnants when the tablets were counted on the next visit.
In summary, low dose diuretic therapy with indapamide resulted in a significant reduction in blood pressure with minimal metabolic derangement. These effects can be precluded even further through use of an every-other-day administration regime without sacrificing blood pressure lowering efficacy. Values are mean SEM. ABP, ambulatory blood pressure.
